This Is the Biggest Risk With Iovance Biotherapeutics Stock

Iovance Biotherapeutics (NASDAQ: IOVA) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy treatment for advanced melanoma, Amtagvi. It gives the business a crucial product to build its operations around.Growth investors were initially bullish on the news, but in recent months, the stock has started to struggle. While there is a lot more optimism surrounding the company, investors need to be aware that the accelerated approval of Amtagvi may not be enough to make Iovance a slam-dunk buy at this point.There's a significant risk investors should understand before investing in the healthcare company. Here's why.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool